Bone Biologics Corp (BBLG) is an emerging biotechnology company primarily centered on the discovery, development, and commercialization of orthobiologic products and medical devices. This distinct focus is oriented towards promoting effective bone healing and regeneration, which is a key challenge in various medical and surgical interventions. Since its inception, Bone Biologics Corp has been dedicatedly engaged in pioneering solutions that enhance the natural mechanisms of bone formation.
BBLG's primary product is the revolutionary recombinant human protein, known as Nell-1, which is designed to direct stem cells to become bone-forming cells. A potential game-changer in the orthobiologics market, Nell-1 represents the culmination of years of careful research and rigorous testing. It has been demonstrated that Nell-1 can significantly boost bone formation in a tightly regulated manner — a remarkable achievement that opens up exciting new avenues in tissue regeneration and repair.
Bone Biologics Corp has a dedicated team of professionals that oversees the development of Nell-1, ensuring stringent quality control and adherence to regulatory compliance. The laboriously developed product has reached a critical point, reflecting the culmination of more than a decade of scientific research and development based on the outcomes of a grant-driven research program at the University of California Los Angeles (UCLA).
In order to catapult the product to the real world and bring the benefits of regenerative medicine closer to patients, Bone Biologics Corp collaborates with top-rated medical institutions and utilizes capital infusion from investors and strategic partners. BBLG's collaboration with the Musculoskeletal Transplant Foundation (MTF), the nation’s largest tissue bank, is noteworthy. This partnership supports the further development of BBLG's groundbreaking technology and the goal of accelerating its product into human clinical trials.
In a nutshell, Bone Biologics Corp embodies an undeterred commitment towards revolutionizing the landscape of orthobiologics. BBLG is proactively shaping the future of bone regeneration and repair through cutting-edge research, innovative product development, and unwavering dedication to improving patient care. As the company's pursuit of excellence continues, its profound impact on the field of regenerative medicine only magnifies. By delivering pioneering solutions that transform lives, Bone Biologics Corp stands as a testament to the power of innovation in the healthcare sector.